ArticleAnnals of medicine2025
The impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Letter to the editor regarding: 'The impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer'.Annals of medicine · 2026Article
- Letter to the editor regarding to 'the impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer'.Annals of medicine · 2026Article
- Regarding: "the impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer".Annals of medicine · 2026Article
- Comment on 'the impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer'.Annals of medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough Body Mass Index (BMI) has been reported to influence breast cancer prognosis, recent evidence challenges the traditional conclusion that high BMI consistently predicts poor prognosis. The aim of this study was to determine the impact of BMI on the efficacy of CDK4/6 inhibitors in patients with metastatic hormone receptor (HR)-positive breast cancer (BC).
methodsWe performed a retrospective chart review of all female patients with metastatic HR-positive BC on a CDK4/6 inhibitor in first- or late-line settings and seen at our academic institution between 2016 and 2023. The primary endpoint was Overall Survival (OS), defined as the time from the start of CDK4/6 inhibitors to death due to any cause.
resultsWe identified 212 patients who had received a CDK4/6 inhibitor in the first- or second-line settings for metastatic HR-positive BC. Of the 212 patients, 53.3% (113) had a low BMI (defined as < 24 kg/m
conclusionIn HR positive advanced breast cancer patients treated with first-line CDK4/6 inhibitors, lower BMI is associated with poorer prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.